Investing in Canada's health and defence emergency readiness to keep Canadians safe at home and abroad
Today, the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, in partnership with the Honourable David J. McGuinty, Minister of National Defence, announced a significant federal investment of $75 million to advance Canadian Blood Services' (CBS) innovative initiative to strengthen Canada's domestic blood and plasma capabilities for health emergencies and provide the Canadian Armed Forces (CAF) with reliable access to critical health care during defence operations. Blood products are essential to CAF operations, supporting trauma care, treatment and emergency response.
The government's investment in the CBS and CAF partnership will strengthen Canada's ability to respond quickly and effectively to large-scale health emergencies and support military operations at home and abroad, including natural disaster response and deployments in difficult and remote environments such as the Arctic. This project will also improve access to effective, made-in-Canada blood products and expand domestic manufacturing so that critical supplies remain safe, secure and available when needed most.
Delivered through the Life Sciences Fund, this investment supports health and defence readiness objectives, including the development of innovative blood product technologies. Strategic investments in projects like this and in domestic life sciences capabilities are essential for protecting Canada's health security, enhancing CAF resiliency and building strong supply chains that can withstand global uncertainty and evolving threats.
In an increasingly dangerous and divided world, the Government of Canada is responding ambitiously and strategically to protect Canadians and ensure the CAF are equipped for new and emerging threats. The government is delivering on these objectives, beginning with Canada's Defence Industrial Strategy and the Prime Minister's recent announcement that Canada has achieved the NATO 2% defence spending target. Investing in Canada's world-class life sciences sector is critical to advancing Canada's defence objectives, while at the same time strengthening our emergency health preparedness and response capabilities.
